May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
In vitro Effect of Combined Dexamethasone and Bevacizumab Treatment on the Viability of Human Retinal Pigment Epithelial Cells After Photodynamic Therapy With Verteporfin
Author Affiliations & Notes
  • S.-W. Kim
    Ophthalmology, Korea Univ. Guro Hosp., Seoul, Republic of Korea
  • K. Huh
    Ophthalmology, Korea Univ. Guro Hosp., Seoul, Republic of Korea
  • J. Oh
    Ophthalmology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  S. Kim, None; K. Huh, None; J. Oh, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 477. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.-W. Kim, K. Huh, J. Oh; In vitro Effect of Combined Dexamethasone and Bevacizumab Treatment on the Viability of Human Retinal Pigment Epithelial Cells After Photodynamic Therapy With Verteporfin. Invest. Ophthalmol. Vis. Sci. 2008;49(13):477. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the in vitro effect of combined dexamethasone and bevacizumab treatment with photodynamic therapy (PDT) using verteporfin on the cell viability of the retinal pigment epithelial (RPE) cells.

Methods: : Human retinal pigment epithelial cells (ARPE-19) were treated with two different concentrations of dexamethasone (0.1 and 0.2 mg/ml) and bevacizumab (0.125 and 0.25 mg/ml) in conjunction with or without verteporfin PDT. Cell viability was measured using cell count (%) and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay at 2 hours, 24 hours, and 48 hours after combined therapy.

Results: : The cell viabilities of ARPE-19 cells, treated with dexamethasone or bevacizumab only, were not significantly different (P > 0.05) from those of untreated controls at all time points and concentrations irrespective of PDT. The lack of cytotoxic effect of combined 0.1 mg/ml dexamethasone and 0.125mg/ml bevacizumab treatment with or without PDT on ARPE-19 cells could be observed at all periods. The MTT assay decreased to 91.3 ± 6.0% (p=0.009), 94.7 ± 4.7% (p=0.045), and 92.9 ± 6.2% (p=0.034) respectively, after 2 hours, 24 hours, and 48 hours of direct exposure to both 0.2mg/ml dexamethasone and 0.25 mg/ml bevacizumab with PDT. The number of viable cells also decreased by 93.4 ± 3.0% (p=0.032), 90.7 ± 6.0% (p=0.001), and 93.5 ± 3.9% (p=0.034) respectively, after 2 hours, 24 hours, and 48 hours of direct exposure to both dexamethasone 0.2 mg/ml and 0.25mg/ml bevacizumab with PDT.

Conclusions: : In vitro, 0.2 mg/ml dexamethasone and 0.25mg/ml bevacizumab combination therapy, usually used for treatment of choroidal neovascularization, is toxic to ARPE-19 cells irrespective of PDT.

Keywords: retinal pigment epithelium • cell survival • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×